Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Cocrystal Pharma, Inc. (COCP) (formerly BioZone Pharmaceuticals, Inc. (BZNE)) and Encourages COCP Investors to Contact the Firm
NEW YORK, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the U.S. District Court of New Jersey on behalf of all persons or entities who purchased or otherwise acquired Cocrystal Pharma, Inc. (COCP) securities between September 23, 2013 through September 7, 2018 (the “Class Period”).
The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) defendants were engaged in a pump-and-dump scheme to artificially inflate Cocrystal’s stock price; (2) this illicit scheme would result in governmental scrutiny, including from the SEC; (3) defendants failed to abide by SEC disclosure regulations; and (4) as a result, defendants’ statements about Cocrystal’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
If you purchased Cocrystal securities during the Class Period or continue to hold shares purchased before the Class Period, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at email@example.com, or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information concerning the Cocrystal Pharma, Inc. lawsuit, please go to https://bespc.com/cocrystal/. For additional information about Bragar Eagel & Squire, P.C. please go to www.bespc.com.